Logo
x

Search

Subscribe Now

Non-small cell Lung cancer

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

  • October 18, 2021
Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lu...

  • September 21, 2021
Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung...

  • September 17, 2021
Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer...

  • September 14, 2021
Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

  • September 14, 2021
BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop & Commercialize Plinabulin in Greater China

BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop & Commercialize Plinabulin in Greater China

  • August 27, 2021
Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

    Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

    • September 9, 2024
    Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

      Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

      • September 9, 2024
      Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer

        Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer

        • September 3, 2024
        Pierre Fabre Laboratories Reports the EC’s Approval of Braftovi Plus Mektovi to Treat Advanced Non-Small Cell Lung Cancer

          Pierre Fabre Laboratories Reports the EC’s Approval of Braftovi Plus Mektovi to Treat Advanced Non-Small Cell Lung Cancer

          • September 2, 2024
          Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)

            Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)

            • August 30, 2024
            Merck Discontinues P-III (KEYNOTE-867 and KEYNOTE-630) Studies Evaluating Keytruda for Cancer Treatment

              Merck Discontinues P-III (KEYNOTE-867 and KEYNOTE-630) Studies Evaluating Keytruda for Cancer Treatment

              • August 29, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.